Phase II randomized, multicenter study of lenalidomide vs best investigator’s choice in relapsed/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) study

Marek Trneny, Thierry Lamy, Jan Walewski, Wojciech Jurczak, David Belada, Jiri Mayer, John Radford, Julia Alexeeva, Dzhelil Osmanov, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Luca Arcaini

    Research output: Contribution to journal › Meeting Abstract › peer-review

    Fingerprint

    Dive into the research topics of 'Phase II randomized, multicenter study of lenalidomide vs best investigator’s choice in relapsed/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) study'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science

    Medicine and Dentistry